Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuji Murakami

Showing results (51-60 of 119) with videos related to

Pageof 12
Sort By:
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|March 13, 2015
Negative prognostic influence of micropapillary pattern in stage IA lung adenocarcinomaNorifumi Tsubokawa, Takahiro Mimae, Shinsuke Sasada, et al.
Journal of Cancer Research and Clinical Oncology|April 14, 2025
Comparison of programmed death ligand-1 expression in preoperative transbronchial lung biopsy and resected specimens in non-small cell lung cancerNaoko Shigeta, Shuji Murakami, Kouji Yamamoto, et al.
Thoracic Cancer|October 6, 2022
Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutationsShuji Murakami, Tomoyuki Yokose, Kanako Shinada, et al.
Journal of Cancer Research and Clinical Oncology|July 28, 2022
Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patientsRyoko Inaba Higashiyama, Hidehito Horinouchi, Aya Kuchiba, et al.
Thoracic Cancer|February 9, 2019
Mixed response to osimertinib and the beneficial effects of additional local therapyYuki Shinno, Yasushi Goto, Jun Sato, et al.
Thoracic Cancer|February 15, 2019
Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancerRyota Shibaki, Shuji Murakami, Yuki Shinno, et al.
Interdisciplinary Cardiovascular and Thoracic Surgery|December 14, 2025
Impact of Phrenic Nerve Repair Using Intercostal Nerve Graft on Diaphragm Function after Thoracic Tumour ResectionTetsuya Isaka, Yui Sueishi, Ikki Takada, et al.
JAMA Oncology|November 22, 2023
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical TrialYusuke Okuma, Kaoru Kubota, Mototsugu Shimokawa, et al.
Future Oncology (London, England)|January 17, 2022
Uncommon <i>EGFR</i> mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901)Yusuke Okuma, Mototsugu Shimokawa, Kana Hashimoto, et al.
Thoracic Cancer|February 21, 2020
Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failureTakaaki Mizuno, Hidehito Horinouchi, Sho Watanabe, et al.
Pageof 12

Showing results (51-60 of 119) with videos related to

Sort By:
Pageof 12
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|March 13, 2015
Negative prognostic influence of micropapillary pattern in stage IA lung adenocarcinomaNorifumi Tsubokawa, Takahiro Mimae, Shinsuke Sasada, et al.
Journal of Cancer Research and Clinical Oncology|April 14, 2025
Comparison of programmed death ligand-1 expression in preoperative transbronchial lung biopsy and resected specimens in non-small cell lung cancerNaoko Shigeta, Shuji Murakami, Kouji Yamamoto, et al.
Thoracic Cancer|October 6, 2022
Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutationsShuji Murakami, Tomoyuki Yokose, Kanako Shinada, et al.
Journal of Cancer Research and Clinical Oncology|July 28, 2022
Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patientsRyoko Inaba Higashiyama, Hidehito Horinouchi, Aya Kuchiba, et al.
Thoracic Cancer|February 9, 2019
Mixed response to osimertinib and the beneficial effects of additional local therapyYuki Shinno, Yasushi Goto, Jun Sato, et al.
Thoracic Cancer|February 15, 2019
Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancerRyota Shibaki, Shuji Murakami, Yuki Shinno, et al.
Interdisciplinary Cardiovascular and Thoracic Surgery|December 14, 2025
Impact of Phrenic Nerve Repair Using Intercostal Nerve Graft on Diaphragm Function after Thoracic Tumour ResectionTetsuya Isaka, Yui Sueishi, Ikki Takada, et al.
JAMA Oncology|November 22, 2023
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical TrialYusuke Okuma, Kaoru Kubota, Mototsugu Shimokawa, et al.
Future Oncology (London, England)|January 17, 2022
Uncommon <i>EGFR</i> mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901)Yusuke Okuma, Mototsugu Shimokawa, Kana Hashimoto, et al.
Thoracic Cancer|February 21, 2020
Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failureTakaaki Mizuno, Hidehito Horinouchi, Sho Watanabe, et al.
Pageof 12